Brown Advisory Inc. Takes $428,000 Position in Enovis Co. (NYSE:ENOV)

Brown Advisory Inc. bought a new stake in shares of Enovis Co. (NYSE:ENOV) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 7,637 shares of the company’s stock, valued at approximately $428,000.

Several other institutional investors and hedge funds also recently made changes to their positions in ENOV. Victory Capital Management Inc. boosted its stake in shares of Enovis by 9.2% during the 3rd quarter. Victory Capital Management Inc. now owns 26,348 shares of the company’s stock valued at $1,389,000 after buying an additional 2,209 shares during the last quarter. Jump Financial LLC lifted its stake in Enovis by 187.0% during the third quarter. Jump Financial LLC now owns 11,469 shares of the company’s stock worth $605,000 after purchasing an additional 7,473 shares during the last quarter. Fox Run Management L.L.C. lifted its stake in Enovis by 36.5% during the third quarter. Fox Run Management L.L.C. now owns 8,049 shares of the company’s stock worth $424,000 after purchasing an additional 2,151 shares during the last quarter. Barclays PLC lifted its stake in Enovis by 31.2% during the third quarter. Barclays PLC now owns 120,783 shares of the company’s stock worth $6,368,000 after purchasing an additional 28,727 shares during the last quarter. Finally, Quantbot Technologies LP bought a new position in Enovis during the third quarter worth $358,000. 98.45% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ENOV has been the topic of several research analyst reports. Canaccord Genuity Group raised their price objective on Enovis from $73.00 to $75.00 and gave the stock a “buy” rating in a research note on Friday, February 23rd. Wells Fargo & Company increased their target price on Enovis from $73.00 to $79.00 and gave the stock an “overweight” rating in a research report on Friday, February 23rd. Needham & Company LLC reaffirmed a “buy” rating and issued a $82.00 target price on shares of Enovis in a research report on Friday, May 3rd. Finally, Stephens initiated coverage on Enovis in a research report on Tuesday, February 13th. They issued an “overweight” rating and a $72.00 target price on the stock. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $75.43.

Enovis Price Performance

Shares of ENOV opened at $50.24 on Monday. The firm has a market capitalization of $2.76 billion, a price-to-earnings ratio of -33.49 and a beta of 1.99. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.03 and a current ratio of 2.10. Enovis Co. has a one year low of $43.04 and a one year high of $66.14. The stock’s fifty day moving average is $56.17 and its 200-day moving average is $56.34.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Thursday, May 2nd. The company reported $0.50 EPS for the quarter, meeting analysts’ consensus estimates of $0.50. The company had revenue of $516.00 million for the quarter, compared to analyst estimates of $505.62 million. Enovis had a positive return on equity of 3.98% and a negative net margin of 4.51%. The company’s quarterly revenue was up 27.0% compared to the same quarter last year. During the same period last year, the company earned $0.44 earnings per share. Equities analysts anticipate that Enovis Co. will post 2.63 EPS for the current year.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.